Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PJA2

Gene summary for PJA2

Gene summary.

Gene information	Species	Human
	Gene symbol	PJA2
	Gene ID	9867
	Gene name	praja ring finger ubiquitin ligase 2
	Gene Alias	Neurodap1
	Cytomap	5q21.3
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	O43164

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9867	PJA2	LZE4T	Human	Esophagus	ESCC	6.36e-18	5.63e-01	0.0811
9867	PJA2	LZE5T	Human	Esophagus	ESCC	5.42e-03	1.62e-01	0.0514
9867	PJA2	LZE7T	Human	Esophagus	ESCC	8.93e-03	2.19e-01	0.0667
9867	PJA2	LZE8T	Human	Esophagus	ESCC	5.94e-05	5.86e-02	0.067
9867	PJA2	LZE20T	Human	Esophagus	ESCC	4.38e-03	5.41e-02	0.0662
9867	PJA2	LZE24T	Human	Esophagus	ESCC	9.34e-11	4.17e-01	0.0596
9867	PJA2	LZE21T	Human	Esophagus	ESCC	2.26e-02	9.44e-02	0.0655
9867	PJA2	LZE6T	Human	Esophagus	ESCC	1.48e-02	2.33e-02	0.0845
9867	PJA2	P1T-E	Human	Esophagus	ESCC	8.88e-07	4.56e-01	0.0875
9867	PJA2	P2T-E	Human	Esophagus	ESCC	2.56e-28	4.16e-01	0.1177
9867	PJA2	P4T-E	Human	Esophagus	ESCC	1.43e-15	4.40e-01	0.1323
9867	PJA2	P5T-E	Human	Esophagus	ESCC	2.58e-18	3.44e-01	0.1327
9867	PJA2	P8T-E	Human	Esophagus	ESCC	3.09e-22	2.53e-01	0.0889
9867	PJA2	P9T-E	Human	Esophagus	ESCC	9.53e-07	2.41e-01	0.1131
9867	PJA2	P10T-E	Human	Esophagus	ESCC	1.93e-17	3.40e-01	0.116
9867	PJA2	P11T-E	Human	Esophagus	ESCC	8.77e-09	4.89e-01	0.1426
9867	PJA2	P12T-E	Human	Esophagus	ESCC	8.16e-18	3.24e-01	0.1122
9867	PJA2	P15T-E	Human	Esophagus	ESCC	4.00e-20	4.10e-01	0.1149
9867	PJA2	P16T-E	Human	Esophagus	ESCC	2.93e-09	4.07e-02	0.1153
9867	PJA2	P17T-E	Human	Esophagus	ESCC	1.46e-09	3.82e-01	0.1278

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:003109818	Esophagus	ESCC	stress-activated protein kinase signaling cascade	154/8552	247/18723	8.53e-08	1.44e-06	154
GO:005140318	Esophagus	ESCC	stress-activated MAPK cascade	147/8552	239/18723	5.43e-07	7.18e-06	147
GO:007030217	Esophagus	ESCC	regulation of stress-activated protein kinase signaling cascade	119/8552	195/18723	1.07e-05	1.01e-04	119
GO:003287217	Esophagus	ESCC	regulation of stress-activated MAPK cascade	116/8552	192/18723	2.63e-05	2.21e-04	116
GO:00072549	Esophagus	ESCC	JNK cascade	102/8552	167/18723	4.22e-05	3.39e-04	102
GO:00463289	Esophagus	ESCC	regulation of JNK cascade	80/8552	133/18723	5.35e-04	2.95e-03	80
GO:00703046	Esophagus	ESCC	positive regulation of stress-activated protein kinase signaling cascade	74/8552	128/18723	3.77e-03	1.53e-02	74
GO:00328745	Esophagus	ESCC	positive regulation of stress-activated MAPK cascade	72/8552	126/18723	6.24e-03	2.29e-02	72
GO:00463302	Esophagus	ESCC	positive regulation of JNK cascade	52/8552	89/18723	1.04e-02	3.56e-02	52
GO:00353297	Esophagus	ESCC	hippo signaling	26/8552	40/18723	1.08e-02	3.66e-02	26
GO:00072543	Liver	NAFLD	JNK cascade	38/1882	167/18723	1.12e-06	5.52e-05	38
GO:00514036	Liver	NAFLD	stress-activated MAPK cascade	47/1882	239/18723	5.26e-06	1.93e-04	47
GO:00310986	Liver	NAFLD	stress-activated protein kinase signaling cascade	48/1882	247/18723	5.89e-06	2.07e-04	48
GO:00463283	Liver	NAFLD	regulation of JNK cascade	28/1882	133/18723	1.19e-04	2.31e-03	28
GO:00703025	Liver	NAFLD	regulation of stress-activated protein kinase signaling cascade	34/1882	195/18723	1.01e-03	1.20e-02	34
GO:00328725	Liver	NAFLD	regulation of stress-activated MAPK cascade	33/1882	192/18723	1.52e-03	1.65e-02	33
GO:0035329	Liver	NAFLD	hippo signaling	10/1882	40/18723	5.20e-03	4.05e-02	10
GO:0046330	Liver	NAFLD	positive regulation of JNK cascade	17/1882	89/18723	6.91e-03	4.87e-02	17
GO:003109812	Liver	Cirrhotic	stress-activated protein kinase signaling cascade	83/4634	247/18723	1.04e-03	7.28e-03	83
GO:005140312	Liver	Cirrhotic	stress-activated MAPK cascade	80/4634	239/18723	1.43e-03	9.54e-03	80

Page: 1 2 3 4 5 6 7

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PJA2

SNV

Missense_Mutation

c.1393N>C

p.Asp465His

p.D465H

O43164

protein_coding

deleterious(0)

probably_damaging(0.979)

TCGA-A8-A08R-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PJA2

SNV

Missense_Mutation

c.680G>A

p.Arg227Lys

p.R227K

O43164

protein_coding

tolerated(0.18)

benign(0.007)

TCGA-AC-A2B8-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

chemo

PJA2

SNV

Missense_Mutation

novel

c.682N>A

p.Asp228Asn

p.D228N

O43164

protein_coding

tolerated(0.06)

benign(0.007)

TCGA-BH-A0HA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PJA2

SNV

Missense_Mutation

c.809N>T

p.Gln270Leu

p.Q270L

O43164

protein_coding

tolerated(0.54)

benign(0)

TCGA-C8-A12P-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PJA2

SNV

Missense_Mutation

c.1682N>A

p.Gly561Glu

p.G561E

O43164

protein_coding

deleterious(0.02)

probably_damaging(1)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PJA2

SNV

Missense_Mutation

c.1108G>A

p.Glu370Lys

p.E370K

O43164

protein_coding

tolerated(0.25)

benign(0.021)

TCGA-E9-A1R7-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

fareston

PJA2

insertion

Frame_Shift_Ins

novel

c.750_751insTTTTTTGAAAGTGTAAGGTGCTTGTATTTTTTTTCCCCCAGTTA

p.Gln251PhefsTer78

p.Q251Ffs*78

O43164

protein_coding

TCGA-A8-A07P-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

5-fluorouracil

PJA2

insertion

In_Frame_Ins

novel

c.642_643insTCATTTATGTCAATGTACAGC

p.Gly214_Leu215insSerPheMetSerMetTyrSer

p.G214_L215insSFMSMYS

O43164

protein_coding

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

PJA2

SNV

Missense_Mutation

c.1764G>T

p.Glu588Asp

p.E588D

O43164

protein_coding

deleterious(0.01)

probably_damaging(0.997)

TCGA-AA-A01R-01

Colorectum

colon adenocarcinoma

Male

<65

III/IV

Chemotherapy

5-fluorouracil

PJA2

SNV

Missense_Mutation

novel

c.1337G>T

p.Gly446Val

p.G446V

O43164

protein_coding

tolerated(0.12)

benign(0.189)

TCGA-AM-5820-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1